Essential Premium

Biopharma Continues to Buoy the IPO Market

Four more companies have either gone public or filed plans in the past week.

Private Credit Series Texas 2026

November 9-10, 2026 | Hotel ZaZa Austin Downtown

Seligman Cuts AI Exposure, Preserving a Nearly 40 Percent Gain

Paul Wick’s tech-focused hedge fund trimmed AI winners before the summer correction, making the fund one of the year’s top performers.

Sponsored

High Beef Prices Test Consumers This Grilling Season

AI Will Help CFM Discover New Sources of Alpha

Why Asia and Europe Are Turning to U.S. Crude Oil

Mulvaney, Quantedge Lead Surging CTAs

Many prominent programs are up by double-digit rates this year after posting strong August results. 

Related Content

Biotech IPO Fever Shows No Signs of Breaking

Stephen Taub

A Jim Simons Market Mystery — Solved?

Richard Teitelbaum

A Tiny Activist Takes on John Malone, Cerberus, and a Cable Giant

Richard Teitelbaum

2026 FTF Fall Workshop

October 27-28, 2026 | The Langham

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram